Clearance of 131I-labeled murine monoclonal antibody from patients' blood by intravenous human anti-murine immunoglobulin antibody
Five patients treated with intraperitoneal 131I-labeled mouse monoclonal antibody for ovarian cancer also received i.v. exogenous polyclonal human anti-murine immunoglobulin antibody. The pharmacokinetics of 131I-labeled monoclonal antibody in these patients were compared with those of 28 other pati...
Gespeichert in:
| Veröffentlicht in: | Cancer research (Chicago, Ill.) Ill.), 1990-02, Vol.50 (3), p.563-567 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 567 |
|---|---|
| container_issue | 3 |
| container_start_page | 563 |
| container_title | Cancer research (Chicago, Ill.) |
| container_volume | 50 |
| creator | STEWART, J. S. W SIVOLAPENKO, G. B HIRD, V DAVIES, K. A. A WALPORT, M RITTER, M. A EPENETOS, A. A |
| description | Five patients treated with intraperitoneal 131I-labeled mouse monoclonal antibody for ovarian cancer also received i.v. exogenous polyclonal human anti-murine immunoglobulin antibody. The pharmacokinetics of 131I-labeled monoclonal antibody in these patients were compared with those of 28 other patients receiving i.p.-radiolabeled monoclonal antibody for the first time without exogenous human anti-murine immunoglobulin, and who had no preexisting endogenous human anti-murine immunoglobulin antibody. Patients receiving i.v. human anti-murine immunoglobulin antibody demonstrated a rapid clearance of 131I-labeled monoclonal antibody from their circulation. The (mean) maximum 131I blood content was 11.4% of the injected activity in patients receiving human anti-murine immunoglobulin antibody compared to 23.3% in patients not given human anti-murine immunoglobulin antibody. Intravenous human anti-murine immunoglobulin antibody decreased the radiation dose to bone marrow (from 131I-labeled monoclonal antibody in the vascular compartment) 4-fold. Following the injection of human anti-murine immunoglobulin antibody, 131I-monoclonal/human anti-murine immunoglobulin antibody immune complexes were rapidly transported to the liver. Antibody dehalogenation in the liver was rapid, with 87% of the injected 131I excreted in 5 days. Despite the efficient hepatic uptake of immune complexes, dehalogenation of monoclonal antibody was so rapid that the radiation dose to liver parenchyma from circulating 131I was decreased 4-fold rather than increased. All patients developed endogenous human anti-murine immunoglobulin antibody 2 to 3 weeks after treatment. |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_pasca</sourceid><recordid>TN_cdi_pubmed_primary_2297697</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2297697</sourcerecordid><originalsourceid>FETCH-LOGICAL-h182t-d0672608be5ad522ffbf4681f7e4715caed307b3dcff84dd69d6781c6de267613</originalsourceid><addsrcrecordid>eNo9kEtLAzEAhIMotVZ_gpCD4CmQZPPaoxQfhYIXPZdkk9hIHmWzK-zVX27VpadhmJnvMGdgSXijkGSMn4MlxlghziS9BFe1fh4tJ5gvwILSVopWLsH3Ojrd69w5WDwkDdmgqI2LzsI09iE7mEouXSxZR6jzEEyxE_R9SfCgh-DyUO-hiaVYaCYY8tDrL5fLWOF-TDr_TdBMCimNuXzEYsYY8ol2DS68jtXdzLoC70-Pb-sXtH193qwftmhPFB2QxUJSgZVxXFtOqffGM6GIl45JwjvtbIOlaWznvWLWitYKqUgnrKNCCtKswO0_9zCa5Ozu0Iek-2k3f3HM7-Zc105H__tKqKeaaAnFTDY_3sRrkw</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Clearance of 131I-labeled murine monoclonal antibody from patients' blood by intravenous human anti-murine immunoglobulin antibody</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>American Association for Cancer Research</source><creator>STEWART, J. S. W ; SIVOLAPENKO, G. B ; HIRD, V ; DAVIES, K. A. A ; WALPORT, M ; RITTER, M. A ; EPENETOS, A. A</creator><creatorcontrib>STEWART, J. S. W ; SIVOLAPENKO, G. B ; HIRD, V ; DAVIES, K. A. A ; WALPORT, M ; RITTER, M. A ; EPENETOS, A. A</creatorcontrib><description>Five patients treated with intraperitoneal 131I-labeled mouse monoclonal antibody for ovarian cancer also received i.v. exogenous polyclonal human anti-murine immunoglobulin antibody. The pharmacokinetics of 131I-labeled monoclonal antibody in these patients were compared with those of 28 other patients receiving i.p.-radiolabeled monoclonal antibody for the first time without exogenous human anti-murine immunoglobulin, and who had no preexisting endogenous human anti-murine immunoglobulin antibody. Patients receiving i.v. human anti-murine immunoglobulin antibody demonstrated a rapid clearance of 131I-labeled monoclonal antibody from their circulation. The (mean) maximum 131I blood content was 11.4% of the injected activity in patients receiving human anti-murine immunoglobulin antibody compared to 23.3% in patients not given human anti-murine immunoglobulin antibody. Intravenous human anti-murine immunoglobulin antibody decreased the radiation dose to bone marrow (from 131I-labeled monoclonal antibody in the vascular compartment) 4-fold. Following the injection of human anti-murine immunoglobulin antibody, 131I-monoclonal/human anti-murine immunoglobulin antibody immune complexes were rapidly transported to the liver. Antibody dehalogenation in the liver was rapid, with 87% of the injected 131I excreted in 5 days. Despite the efficient hepatic uptake of immune complexes, dehalogenation of monoclonal antibody was so rapid that the radiation dose to liver parenchyma from circulating 131I was decreased 4-fold rather than increased. All patients developed endogenous human anti-murine immunoglobulin antibody 2 to 3 weeks after treatment.</description><identifier>ISSN: 0008-5472</identifier><identifier>EISSN: 1538-7445</identifier><identifier>PMID: 2297697</identifier><identifier>CODEN: CNREA8</identifier><language>eng</language><publisher>Philadelphia, PA: American Association for Cancer Research</publisher><subject>Antibodies, Anti-Idiotypic - administration & dosage ; Antibodies, Monoclonal - pharmacokinetics ; Antibodies, Monoclonal - therapeutic use ; Antigen-Antibody Complex - metabolism ; Antineoplastic agents ; Biological and medical sciences ; Bone Marrow - radiation effects ; Chemotherapy ; Female ; Humans ; Immunization, Passive ; Immunotherapy ; Iodine Radioisotopes - adverse effects ; Liver - radiation effects ; Medical sciences ; Membrane Glycoproteins - immunology ; Mucin-1 ; Ovarian Neoplasms - therapy ; Pharmacology. Drug treatments ; Radiotherapy Dosage</subject><ispartof>Cancer research (Chicago, Ill.), 1990-02, Vol.50 (3), p.563-567</ispartof><rights>1990 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,781,785</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=6912047$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/2297697$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>STEWART, J. S. W</creatorcontrib><creatorcontrib>SIVOLAPENKO, G. B</creatorcontrib><creatorcontrib>HIRD, V</creatorcontrib><creatorcontrib>DAVIES, K. A. A</creatorcontrib><creatorcontrib>WALPORT, M</creatorcontrib><creatorcontrib>RITTER, M. A</creatorcontrib><creatorcontrib>EPENETOS, A. A</creatorcontrib><title>Clearance of 131I-labeled murine monoclonal antibody from patients' blood by intravenous human anti-murine immunoglobulin antibody</title><title>Cancer research (Chicago, Ill.)</title><addtitle>Cancer Res</addtitle><description>Five patients treated with intraperitoneal 131I-labeled mouse monoclonal antibody for ovarian cancer also received i.v. exogenous polyclonal human anti-murine immunoglobulin antibody. The pharmacokinetics of 131I-labeled monoclonal antibody in these patients were compared with those of 28 other patients receiving i.p.-radiolabeled monoclonal antibody for the first time without exogenous human anti-murine immunoglobulin, and who had no preexisting endogenous human anti-murine immunoglobulin antibody. Patients receiving i.v. human anti-murine immunoglobulin antibody demonstrated a rapid clearance of 131I-labeled monoclonal antibody from their circulation. The (mean) maximum 131I blood content was 11.4% of the injected activity in patients receiving human anti-murine immunoglobulin antibody compared to 23.3% in patients not given human anti-murine immunoglobulin antibody. Intravenous human anti-murine immunoglobulin antibody decreased the radiation dose to bone marrow (from 131I-labeled monoclonal antibody in the vascular compartment) 4-fold. Following the injection of human anti-murine immunoglobulin antibody, 131I-monoclonal/human anti-murine immunoglobulin antibody immune complexes were rapidly transported to the liver. Antibody dehalogenation in the liver was rapid, with 87% of the injected 131I excreted in 5 days. Despite the efficient hepatic uptake of immune complexes, dehalogenation of monoclonal antibody was so rapid that the radiation dose to liver parenchyma from circulating 131I was decreased 4-fold rather than increased. All patients developed endogenous human anti-murine immunoglobulin antibody 2 to 3 weeks after treatment.</description><subject>Antibodies, Anti-Idiotypic - administration & dosage</subject><subject>Antibodies, Monoclonal - pharmacokinetics</subject><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>Antigen-Antibody Complex - metabolism</subject><subject>Antineoplastic agents</subject><subject>Biological and medical sciences</subject><subject>Bone Marrow - radiation effects</subject><subject>Chemotherapy</subject><subject>Female</subject><subject>Humans</subject><subject>Immunization, Passive</subject><subject>Immunotherapy</subject><subject>Iodine Radioisotopes - adverse effects</subject><subject>Liver - radiation effects</subject><subject>Medical sciences</subject><subject>Membrane Glycoproteins - immunology</subject><subject>Mucin-1</subject><subject>Ovarian Neoplasms - therapy</subject><subject>Pharmacology. Drug treatments</subject><subject>Radiotherapy Dosage</subject><issn>0008-5472</issn><issn>1538-7445</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1990</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kEtLAzEAhIMotVZ_gpCD4CmQZPPaoxQfhYIXPZdkk9hIHmWzK-zVX27VpadhmJnvMGdgSXijkGSMn4MlxlghziS9BFe1fh4tJ5gvwILSVopWLsH3Ojrd69w5WDwkDdmgqI2LzsI09iE7mEouXSxZR6jzEEyxE_R9SfCgh-DyUO-hiaVYaCYY8tDrL5fLWOF-TDr_TdBMCimNuXzEYsYY8ol2DS68jtXdzLoC70-Pb-sXtH193qwftmhPFB2QxUJSgZVxXFtOqffGM6GIl45JwjvtbIOlaWznvWLWitYKqUgnrKNCCtKswO0_9zCa5Ozu0Iek-2k3f3HM7-Zc105H__tKqKeaaAnFTDY_3sRrkw</recordid><startdate>19900201</startdate><enddate>19900201</enddate><creator>STEWART, J. S. W</creator><creator>SIVOLAPENKO, G. B</creator><creator>HIRD, V</creator><creator>DAVIES, K. A. A</creator><creator>WALPORT, M</creator><creator>RITTER, M. A</creator><creator>EPENETOS, A. A</creator><general>American Association for Cancer Research</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope></search><sort><creationdate>19900201</creationdate><title>Clearance of 131I-labeled murine monoclonal antibody from patients' blood by intravenous human anti-murine immunoglobulin antibody</title><author>STEWART, J. S. W ; SIVOLAPENKO, G. B ; HIRD, V ; DAVIES, K. A. A ; WALPORT, M ; RITTER, M. A ; EPENETOS, A. A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-h182t-d0672608be5ad522ffbf4681f7e4715caed307b3dcff84dd69d6781c6de267613</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1990</creationdate><topic>Antibodies, Anti-Idiotypic - administration & dosage</topic><topic>Antibodies, Monoclonal - pharmacokinetics</topic><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>Antigen-Antibody Complex - metabolism</topic><topic>Antineoplastic agents</topic><topic>Biological and medical sciences</topic><topic>Bone Marrow - radiation effects</topic><topic>Chemotherapy</topic><topic>Female</topic><topic>Humans</topic><topic>Immunization, Passive</topic><topic>Immunotherapy</topic><topic>Iodine Radioisotopes - adverse effects</topic><topic>Liver - radiation effects</topic><topic>Medical sciences</topic><topic>Membrane Glycoproteins - immunology</topic><topic>Mucin-1</topic><topic>Ovarian Neoplasms - therapy</topic><topic>Pharmacology. Drug treatments</topic><topic>Radiotherapy Dosage</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>STEWART, J. S. W</creatorcontrib><creatorcontrib>SIVOLAPENKO, G. B</creatorcontrib><creatorcontrib>HIRD, V</creatorcontrib><creatorcontrib>DAVIES, K. A. A</creatorcontrib><creatorcontrib>WALPORT, M</creatorcontrib><creatorcontrib>RITTER, M. A</creatorcontrib><creatorcontrib>EPENETOS, A. A</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><jtitle>Cancer research (Chicago, Ill.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>STEWART, J. S. W</au><au>SIVOLAPENKO, G. B</au><au>HIRD, V</au><au>DAVIES, K. A. A</au><au>WALPORT, M</au><au>RITTER, M. A</au><au>EPENETOS, A. A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clearance of 131I-labeled murine monoclonal antibody from patients' blood by intravenous human anti-murine immunoglobulin antibody</atitle><jtitle>Cancer research (Chicago, Ill.)</jtitle><addtitle>Cancer Res</addtitle><date>1990-02-01</date><risdate>1990</risdate><volume>50</volume><issue>3</issue><spage>563</spage><epage>567</epage><pages>563-567</pages><issn>0008-5472</issn><eissn>1538-7445</eissn><coden>CNREA8</coden><abstract>Five patients treated with intraperitoneal 131I-labeled mouse monoclonal antibody for ovarian cancer also received i.v. exogenous polyclonal human anti-murine immunoglobulin antibody. The pharmacokinetics of 131I-labeled monoclonal antibody in these patients were compared with those of 28 other patients receiving i.p.-radiolabeled monoclonal antibody for the first time without exogenous human anti-murine immunoglobulin, and who had no preexisting endogenous human anti-murine immunoglobulin antibody. Patients receiving i.v. human anti-murine immunoglobulin antibody demonstrated a rapid clearance of 131I-labeled monoclonal antibody from their circulation. The (mean) maximum 131I blood content was 11.4% of the injected activity in patients receiving human anti-murine immunoglobulin antibody compared to 23.3% in patients not given human anti-murine immunoglobulin antibody. Intravenous human anti-murine immunoglobulin antibody decreased the radiation dose to bone marrow (from 131I-labeled monoclonal antibody in the vascular compartment) 4-fold. Following the injection of human anti-murine immunoglobulin antibody, 131I-monoclonal/human anti-murine immunoglobulin antibody immune complexes were rapidly transported to the liver. Antibody dehalogenation in the liver was rapid, with 87% of the injected 131I excreted in 5 days. Despite the efficient hepatic uptake of immune complexes, dehalogenation of monoclonal antibody was so rapid that the radiation dose to liver parenchyma from circulating 131I was decreased 4-fold rather than increased. All patients developed endogenous human anti-murine immunoglobulin antibody 2 to 3 weeks after treatment.</abstract><cop>Philadelphia, PA</cop><pub>American Association for Cancer Research</pub><pmid>2297697</pmid><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0008-5472 |
| ispartof | Cancer research (Chicago, Ill.), 1990-02, Vol.50 (3), p.563-567 |
| issn | 0008-5472 1538-7445 |
| language | eng |
| recordid | cdi_pubmed_primary_2297697 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; American Association for Cancer Research |
| subjects | Antibodies, Anti-Idiotypic - administration & dosage Antibodies, Monoclonal - pharmacokinetics Antibodies, Monoclonal - therapeutic use Antigen-Antibody Complex - metabolism Antineoplastic agents Biological and medical sciences Bone Marrow - radiation effects Chemotherapy Female Humans Immunization, Passive Immunotherapy Iodine Radioisotopes - adverse effects Liver - radiation effects Medical sciences Membrane Glycoproteins - immunology Mucin-1 Ovarian Neoplasms - therapy Pharmacology. Drug treatments Radiotherapy Dosage |
| title | Clearance of 131I-labeled murine monoclonal antibody from patients' blood by intravenous human anti-murine immunoglobulin antibody |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-14T16%3A11%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_pasca&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clearance%20of%20131I-labeled%20murine%20monoclonal%20antibody%20from%20patients'%20blood%20by%20intravenous%20human%20anti-murine%20immunoglobulin%20antibody&rft.jtitle=Cancer%20research%20(Chicago,%20Ill.)&rft.au=STEWART,%20J.%20S.%20W&rft.date=1990-02-01&rft.volume=50&rft.issue=3&rft.spage=563&rft.epage=567&rft.pages=563-567&rft.issn=0008-5472&rft.eissn=1538-7445&rft.coden=CNREA8&rft_id=info:doi/&rft_dat=%3Cpubmed_pasca%3E2297697%3C/pubmed_pasca%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/2297697&rfr_iscdi=true |